-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network September 7 News
Facing kickback allegations
Abbott pays $160 million in compensation
In mid-August, the U.
S.
Department of Justice announced that Abbott had agreed to pay 160 million U.
S.
dollars to resolve allegations that its subsidiaries provided diabetic patients with free blood glucose meters and other rebates to defraud medical insurance reimbursement
.
S.
Department of Justice announced that Abbott had agreed to pay 160 million U.
S.
dollars to resolve allegations that its subsidiaries provided diabetic patients with free blood glucose meters and other rebates to defraud medical insurance reimbursement
.
These allegations were made by former employees of Arriva Medical's call center.
Arriva's parent company, Alere, was acquired by Abbott in October 2017
.
Arriva's parent company, Alere, was acquired by Abbott in October 2017
.
According to the whistleblower, Arriva provides free blood glucose meters, encourages patients to purchase more testing supplies, and regularly waives the co-payment part for medical insurance patients.
The US Department of Justice stated that the department has continued this behavior from April 2010 to the end of 2016.
.
The US Department of Justice stated that the department has continued this behavior from April 2010 to the end of 2016.
.
Arriva was once the largest direct mail supplier of medical insurance diabetes testing products in the United States.
Medical device company Alere acquired Arriva in November 2011, and later Abbott acquired Alere in 2017
.
Medical device company Alere acquired Arriva in November 2011, and later Abbott acquired Alere in 2017
.
It is not difficult to see from the above incidents that the parent company shall bear responsibility for the alleged kickback accusation by the subsidiary of an overseas enterprise.
This is clearly stipulated in the Foreign Corrupt Practices Act promulgated by the United States
.
It may seem unreasonable, but in fact, it is through strengthening the responsibility of the parent company to force it to actively restrain its subsidiaries, and ultimately maintain a good competitive environment in the market
.
This is clearly stipulated in the Foreign Corrupt Practices Act promulgated by the United States
.
It may seem unreasonable, but in fact, it is through strengthening the responsibility of the parent company to force it to actively restrain its subsidiaries, and ultimately maintain a good competitive environment in the market
.
Not only that, regardless of whether it is the suspected kickback or bribery cases of these company subsidiaries or employees, the company must be held responsible, and often have to pay huge indemnities for this:
Last October, Medtronic agreed to pay a $8.
1 million fine to the U.
S.
Department of Justice to quell its case of paying kickbacks to neurosurgeons in South Dakota
.
1 million fine to the U.
S.
Department of Justice to quell its case of paying kickbacks to neurosurgeons in South Dakota
.
In January last year, in order to settle allegations of kickbacks related to the company’s sleep-disordered devices, ResMed paid $37.
5 million in compensation
5 million in compensation
Compared with the "huge compensation" of foreign companies such as Abbott and Medtronic, in contrast to domestic medical device procurement corruption cases, few domestic companies have paid the price for this, which is extremely ironic
.
.
Domestic bribery cases are endless
Acting why business into a "culprit"?
For a long time, kickbacks and bribery cases in China's medical industry have been repeatedly banned, but in the end, the dean was down and the dealers and medical representatives were taken away
.
.
At the beginning of this year, Wu Wenxia, the former director of the Special Inspection Section of Panzhihua Maternity and Child Health Hospital, took advantage of her position to receive RMB 850,000 in cash from medical equipment sales personnel, involving a number of giant machinery companies, and these companies involved in the case pushed them after the incident.
It even says "not responsible for managing sales"
.
It even says "not responsible for managing sales"
.
In August of this year, a medical device seller in Jinan offered bribes to Duan Moumou, the former president of Zibo People's Hospital.
In the end, the medical device representative and the president were arrested and sentenced by the supervisory authority, and the relevant device company went into hiding
.
In the end, the medical device representative and the president were arrested and sentenced by the supervisory authority, and the relevant device company went into hiding
.
Different from foreign marketing models that directly face patients and medical institutions, the domestic agency system has become a protective umbrella for these companies to a certain extent
.
But we all know that "a series of commercial promotion actions in the process of
medical device sales are almost impossible to complete without the support of the headquarters of foreign companies in technology, after-sales, and operation .
" Like pharmaceuticals , a "blacklist system" that goes to the manufacturing company is adopted, so the trick of "dumping the pot" has repeatedly worked
.
.
But we all know that "a series of commercial promotion actions in the process of
medical device sales are almost impossible to complete without the support of the headquarters of foreign companies in technology, after-sales, and operation .
" Like pharmaceuticals , a "blacklist system" that goes to the manufacturing company is adopted, so the trick of "dumping the pot" has repeatedly worked
.
In response to the frequent occurrence of medical rebates, relevant state departments have successively issued relevant regulations
.
.
Medical device manufacturers are severely punished for dishonesty!
The era of rebate gate "traceability" is here
In September last year, the National Medical Insurance Administration implemented a credit evaluation system for medical price recruitment and procurement, which can be said to be a "revolutionary" policy
.
.
If a company bribing medical system personnel or falsely issuing invoices violates any of the regulations, in addition to being included in “serious dishonesty”, it will be reminded and warned by the collection center based on the severity, suspended or permanently banned, and more serious will be Facing "prison disaster"
.
.
After that, the National Medical Insurance Administration and the Supreme People’s Court jointly signed the "Memorandum of Cooperation on the Information Exchange and Sharing of Commercial Bribery Cases in the Pharmaceutical Field", established a regular notification system for commercial bribery cases in the pharmaceutical field, and established corporate credit information with the National Central Procurement Supporting implementation of the evaluation system
.
.
The issuance of these two documents is undoubtedly a huge blow to those companies that have been relying on kickbacks, bribery and other improper behaviors to carry out sales with gold.
Those companies that are often on the list of bribery cases are engaged in centralized procurement and large-scale procurement.
It is bound to be at a competitive disadvantage
.
At a time when various units of the country are severely cracking down on commercial bribery, whether it is a medical device company or a relevant sales representative, it must abandon the idea of "relying on kickbacks to find a way out" and always adhere to legal and compliant industry standards
.
Those companies that are often on the list of bribery cases are engaged in centralized procurement and large-scale procurement.
It is bound to be at a competitive disadvantage
.
At a time when various units of the country are severely cracking down on commercial bribery, whether it is a medical device company or a relevant sales representative, it must abandon the idea of "relying on kickbacks to find a way out" and always adhere to legal and compliant industry standards
.
Medical Network September 7 News
Facing kickback allegations
Abbott pays $160 million in compensation
In mid-August, the U.
S.
Department of Justice announced that Abbott had agreed to pay 160 million U.
S.
dollars to resolve allegations that its subsidiaries provided diabetic patients with free blood glucose meters and other rebates to defraud medical insurance reimbursement
.
S.
Department of Justice announced that Abbott had agreed to pay 160 million U.
S.
dollars to resolve allegations that its subsidiaries provided diabetic patients with free blood glucose meters and other rebates to defraud medical insurance reimbursement
.
These allegations were made by former employees of Arriva Medical's call center.
Arriva's parent company, Alere, was acquired by Abbott in October 2017
.
Arriva's parent company, Alere, was acquired by Abbott in October 2017
.
According to the whistleblower, Arriva provides free blood glucose meters, encourages patients to purchase more testing supplies, and regularly waives the co-payment part for medical insurance patients.
The US Department of Justice stated that the department has continued this behavior from April 2010 to the end of 2016.
.
The US Department of Justice stated that the department has continued this behavior from April 2010 to the end of 2016.
.
Arriva was once the largest direct mail supplier of medical insurance diabetes testing products in the United States.
Medical device company Alere acquired Arriva in November 2011, and later Abbott acquired Alere in 2017
.
Medical device company Alere acquired Arriva in November 2011, and later Abbott acquired Alere in 2017
.
It is not difficult to see from the above incidents that the parent company shall bear responsibility for the alleged kickback accusation by the subsidiary of an overseas enterprise.
This is clearly stipulated in the Foreign Corrupt Practices Act promulgated by the United States
.
It may seem unreasonable, but in fact, it is through strengthening the responsibility of the parent company to force it to actively restrain its subsidiaries, and ultimately maintain a good competitive environment in the market
.
This is clearly stipulated in the Foreign Corrupt Practices Act promulgated by the United States
.
It may seem unreasonable, but in fact, it is through strengthening the responsibility of the parent company to force it to actively restrain its subsidiaries, and ultimately maintain a good competitive environment in the market
.
Not only that, regardless of whether it is the suspected kickback or bribery cases of these company subsidiaries or employees, the company must be held responsible, and often have to pay huge indemnities for this:
Last October, Medtronic agreed to pay a $8.
1 million fine to the U.
S.
Department of Justice to quell its case of paying kickbacks to neurosurgeons in South Dakota
.
1 million fine to the U.
S.
Department of Justice to quell its case of paying kickbacks to neurosurgeons in South Dakota
.
In January last year, in order to settle allegations of kickbacks related to the company’s sleep-disordered devices, ResMed paid $37.
5 million in compensation
5 million in compensation
Compared with the "huge compensation" of foreign companies such as Abbott and Medtronic, in contrast to domestic medical device procurement corruption cases, few domestic companies have paid the price for this, which is extremely ironic
.
.
Domestic bribery cases are endless
Acting why business into a "culprit"?
For a long time, kickbacks and bribery cases in China's medical industry have been repeatedly banned, but in the end, the dean was down and the dealers and medical representatives were taken away
.
.
At the beginning of this year, Wu Wenxia, the former director of the Special Inspection Section of Panzhihua Maternity and Child Health Hospital, took advantage of her position to receive RMB 850,000 in cash from medical equipment sales personnel, involving a number of giant machinery companies, and these companies involved in the case pushed them after the incident.
It even says "not responsible for managing sales"
.
It even says "not responsible for managing sales"
.
In August of this year, a medical device seller in Jinan offered bribes to Duan Moumou, the former president of Zibo People's Hospital.
In the end, the medical device representative and the president were arrested and sentenced by the supervisory authority, and the relevant device company went into hiding
.
In the end, the medical device representative and the president were arrested and sentenced by the supervisory authority, and the relevant device company went into hiding
.
Different from foreign marketing models that directly face patients and medical institutions, the domestic agency system has become a protective umbrella for these companies to a certain extent
.
But we all know that "a series of commercial promotion actions in the process of
medical device sales are almost impossible to complete without the support of the headquarters of foreign companies in technology, after-sales, and operation .
" Like pharmaceuticals , a "blacklist system" that goes to the manufacturing company is adopted, so the trick of "dumping the pot" has repeatedly worked
.
.
But we all know that "a series of commercial promotion actions in the process of
medical device sales are almost impossible to complete without the support of the headquarters of foreign companies in technology, after-sales, and operation .
" Like pharmaceuticals , a "blacklist system" that goes to the manufacturing company is adopted, so the trick of "dumping the pot" has repeatedly worked
.
In response to the frequent occurrence of medical rebates, relevant state departments have successively issued relevant regulations
.
.
Medical device manufacturers are severely punished for dishonesty!
The era of rebate gate "traceability" is here
In September last year, the National Medical Insurance Administration implemented a credit evaluation system for medical price recruitment and procurement, which can be said to be a "revolutionary" policy
.
.
If a company bribing medical system personnel or falsely issuing invoices violates any of the regulations, in addition to being included in “serious dishonesty”, it will be reminded and warned by the collection center based on the severity, suspended or permanently banned, and more serious will be Facing "prison disaster"
.
.
After that, the National Medical Insurance Administration and the Supreme People’s Court jointly signed the "Memorandum of Cooperation on the Information Exchange and Sharing of Commercial Bribery Cases in the Pharmaceutical Field", established a regular notification system for commercial bribery cases in the pharmaceutical field, and established corporate credit information with the National Central Procurement Supporting implementation of the evaluation system
.
.
The issuance of these two documents is undoubtedly a huge blow to those companies that have been relying on kickbacks, bribery and other improper behaviors to carry out sales with gold.
Those companies that are often on the list of bribery cases are engaged in centralized procurement and large-scale procurement.
It is bound to be at a competitive disadvantage
.
At a time when various units of the country are severely cracking down on commercial bribery, whether it is a medical device company or a relevant sales representative, it must abandon the idea of "relying on kickbacks to find a way out" and always adhere to legal and compliant industry standards
.
Those companies that are often on the list of bribery cases are engaged in centralized procurement and large-scale procurement.
It is bound to be at a competitive disadvantage
.
At a time when various units of the country are severely cracking down on commercial bribery, whether it is a medical device company or a relevant sales representative, it must abandon the idea of "relying on kickbacks to find a way out" and always adhere to legal and compliant industry standards
.
Medical Network September 7 News
Facing kickback allegations
Facing kickback allegations Abbott pays $160 million in compensation
Abbott pays $160 million in compensation In mid-August, the U.
S.
Department of Justice announced that Abbott had agreed to pay 160 million U.
S.
dollars to resolve allegations that its subsidiaries provided diabetic patients with free blood glucose meters and other rebates to defraud medical insurance reimbursement
.
S.
Department of Justice announced that Abbott had agreed to pay 160 million U.
S.
dollars to resolve allegations that its subsidiaries provided diabetic patients with free blood glucose meters and other rebates to defraud medical insurance reimbursement
.
These allegations were made by former employees of Arriva Medical's call center.
Arriva's parent company, Alere, was acquired by Abbott in October 2017
.
Arriva's parent company, Alere, was acquired by Abbott in October 2017
.
According to the whistleblower, Arriva provides free blood glucose meters, encourages patients to purchase more testing supplies, and regularly waives the co-payment part for medical insurance patients.
The US Department of Justice stated that the department has continued this behavior from April 2010 to the end of 2016.
.
The US Department of Justice stated that the department has continued this behavior from April 2010 to the end of 2016.
.
Arriva was once the largest direct mail supplier of medical insurance diabetes testing products in the United States.
Medical device company Alere acquired Arriva in November 2011, and later Abbott acquired Alere in 2017
.
Medical device company Alere acquired Arriva in November 2011, and later Abbott acquired Alere in 2017
.
It is not difficult to see from the above incidents that the parent company shall bear responsibility for the alleged kickback accusation by the subsidiary of an overseas enterprise.
This is clearly stipulated in the Foreign Corrupt Practices Act promulgated by the United States
.
It may seem unreasonable, but in fact, it is through strengthening the responsibility of the parent company to force it to actively restrain its subsidiaries, and ultimately maintain a good competitive environment in the market
.
This is clearly stipulated in the Foreign Corrupt Practices Act promulgated by the United States
.
It may seem unreasonable, but in fact, it is through strengthening the responsibility of the parent company to force it to actively restrain its subsidiaries, and ultimately maintain a good competitive environment in the market
.
Not only that, regardless of whether it is the suspected kickback or bribery cases of these company subsidiaries or employees, the company must be held responsible, and often have to pay huge indemnities for this:
Last October, Medtronic agreed to pay a $8.
1 million fine to the U.
S.
Department of Justice to quell its case of paying kickbacks to neurosurgeons in South Dakota
.
1 million fine to the U.
S.
Department of Justice to quell its case of paying kickbacks to neurosurgeons in South Dakota
.
In January last year, in order to settle allegations of kickbacks related to the company’s sleep-disordered devices, ResMed paid $37.
5 million in compensation
5 million in compensation
Compared with the "huge compensation" of foreign companies such as Abbott and Medtronic, in contrast to domestic medical device procurement corruption cases, few domestic companies have paid the price for this, which is extremely ironic
.
.
Domestic bribery cases are endless
Domestic bribery cases are endless Acting why business into a "culprit"?
Acting Acting Actingwhy business into a "culprit"? For a long time, kickbacks and bribery cases in China's medical industry have been repeatedly banned, but in the end, the dean was down and the dealers and medical representatives were taken away
.
.
At the beginning of this year, Wu Wenxia, the former director of the Special Inspection Section of Panzhihua Maternity and Child Health Hospital, took advantage of her position to receive RMB 850,000 in cash from medical equipment sales personnel, involving a number of giant machinery companies, and these companies involved in the case pushed them after the incident.
It even says "not responsible for managing sales"
.
It even says "not responsible for managing sales"
.
In August of this year, a medical device seller in Jinan offered bribes to Duan Moumou, the former president of Zibo People's Hospital.
In the end, the medical device representative and the president were arrested and sentenced by the supervisory authority, and the relevant device company went into hiding
.
Medical equipment medical equipment medical equipmentIn the end, the medical device representative and the president were arrested and sentenced by the supervisory authority, and the relevant device company went into hiding
.
Different from foreign marketing models that directly face patients and medical institutions, the domestic agency system has become a protective umbrella for these companies to a certain extent
.
But we all know that "a series of commercial promotion actions in the process of
medical device sales are almost impossible to complete without the support of the headquarters of foreign companies in technology, after-sales, and operation .
" Like pharmaceuticals , a "blacklist system" that goes to the manufacturing company is adopted, so the trick of "dumping the pot" has repeatedly worked
.
Enterprise enterprise enterprise medicine medicine medicine.
But we all know that "a series of commercial promotion actions in the process of
medical device sales are almost impossible to complete without the support of the headquarters of foreign companies in technology, after-sales, and operation .
" Like pharmaceuticals , a "blacklist system" that goes to the manufacturing company is adopted, so the trick of "dumping the pot" has repeatedly worked
.
In response to the frequent occurrence of medical rebates, relevant state departments have successively issued relevant regulations
.
Medicine Medicine Medicine.
Medical device manufacturers are severely punished for dishonesty!
Medical device manufacturers are severely punished for dishonesty! The era of rebate gate "traceability" is here
The era of rebate gate "traceability" is here In September last year, the National Medical Insurance Administration implemented a credit evaluation system for medical price recruitment and procurement, which can be said to be a "revolutionary" policy
.
.
If a company bribing medical system personnel or falsely issuing invoices violates any of the regulations, in addition to being included in “serious dishonesty”, it will be reminded and warned by the collection center based on the severity, suspended or permanently banned, and more serious will be Facing "prison disaster"
.
.
After that, the National Medical Insurance Administration and the Supreme People’s Court jointly signed the "Memorandum of Cooperation on the Information Exchange and Sharing of Commercial Bribery Cases in the Pharmaceutical Field", established a regular notification system for commercial bribery cases in the pharmaceutical field, and established corporate credit information with the National Central Procurement Supporting implementation of the evaluation system
.
.
The issuance of these two documents is undoubtedly a huge blow to those companies that have been relying on kickbacks, bribery and other improper behaviors to carry out sales with gold.
Those companies that are often on the list of bribery cases are engaged in centralized procurement and large-scale procurement.
It is bound to be at a competitive disadvantage
.
At a time when various units of the country are severely cracking down on commercial bribery, whether it is a medical device company or a relevant sales representative, it must abandon the idea of "relying on kickbacks to find a way out" and always adhere to legal and compliant industry standards
.
Those companies that are often on the list of bribery cases are engaged in centralized procurement and large-scale procurement.
It is bound to be at a competitive disadvantage
.
At a time when various units of the country are severely cracking down on commercial bribery, whether it is a medical device company or a relevant sales representative, it must abandon the idea of "relying on kickbacks to find a way out" and always adhere to legal and compliant industry standards
.
![2-(Hydroxymethyl)benzo[b]thiophene](https://file.echemi.com/fileManage/upload/cas/593/e79a972f-b55d-4dc1-9113-841c417e0a89.png)
